Immunotherapy: A potential adjunctive treatment for fungal infection

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 511-516

  Kullberg, Bart Jan ^a   Van De Veerdonk, Frank ^a   Netea, Mihai G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Candidiasis; Disease susceptibility; Fungal infections; Immunogenetics; Immunotherapy

Indexed keywords

FLUCONAZOLE; FUNGUS VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SAP2 VACCINE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CELL POPULATION; GENETIC SUSCEPTIBILITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; INVASIVE CANDIDIASIS; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; VAGINA CANDIDIASIS; ANTIFUNGAL RESISTANCE; CANDIDA; DRUG EFFECTS; GENETIC ASSOCIATION; HOST PATHOGEN INTERACTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; RISK FACTOR;

ADJUVANTS, IMMUNOLOGIC; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; GENOME-WIDE ASSOCIATION STUDY; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; RISK FACTORS; TH1 CELLS; TH17 CELLS;

EID: 84927799453     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000105     Document Type: Review

References (52)

1. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult nonneutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35:55-62.
2. Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance1) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74:323-331.
3. Diekema D, Arbefeville S, Boyken L, et al. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis 2012; 73:45-48.
4. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110-1122.
5. Eschenauer GA, Carver PL, Lin SW, et al. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. J Antimicrob Chemother 2013; 68:922-926.
6. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-2482.
7. Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54:1739-1746.
8. van de Veerdonk FL, Kullberg BJ, Netea MG. Adjunctive immunotherapy with recombinant cytokines for the treatment of disseminated candidiasis. Clin Microbiol Infect 2012; 18:112-119.
9. Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6:67-78.
10. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11:275-288.
11. Gow NA, van de Veerdonk FL, Brown AJ, Netea MG. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 2012; 10:112-122.
12. Lowman DW, Greene RR, Bearden DW, et al. Novel structural features in Candida albicans hyphal glucan provide a basis for differential innate immune recognition of hyphae versus yeast. J Biol Chem 2014; 289:3432-3443.
13. Gringhuis SI, Kaptein TM, Wevers BA, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat Immunol 2012; 13:246-254.
14. Hernandez-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe 2012; 11:425-435.
15. Gazendam RP, van Hamme JL, Tool AT, et al. Two independent killing mechanisms of Candida albicans by human neutrophils: evidence from innate immunity defects. Blood 2014; 124:590-597.
16. Roy RM, Klein BS. Dendritic cells in antifungal immunity and vaccine design. Cell Host Microbe 2012; 11:436-446.
17. Wuthrich M, Deepe GS Jr, Klein B. Adaptive immunity to fungi. Annu Rev Immunol 2012; 30:115-148.
18. Sutmuller RP, den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116:485-494.
19. Puel A, Cypowyj S, Marodi L, et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012; 12:616-622.
20. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332:65-68.
21. van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54-61.
22. Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635-1648.
23. Puel A, Doffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010; 207:291-297.
24. Kisand K, Boe Wolff AS, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207:299-308.
25. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448:1058-1062.
26. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361:1760-1767.
27. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361:1727-1735.
28. Lanternier F, Pathan S, VincentQB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 2013; 369:1704-1714.
29. Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012; 484:514-518.
30. Smeekens SP, van de Veerdonk FL, Kullberg BJ, Netea MG. Genetic susceptibility to Candida infections. EMBO Mol Med 2013; 5:805-813.
31. Woehrle T, Du W, Goetz A, et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008; 41:322-329.
32. Nahum A, Dadi H, Bates A, Roifman CM. The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol 2011; 127:528-531.
33. Plantinga TS, Johnson MD, Scott WK, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 2012; 205:934-943.
34. Johnson MD, Plantinga TS, van de Vosse E, et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis 2012; 54:502-510.
35. Smeekens SP, Ng A, Kumar V, et al. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun 2013; 4:1342.
36. Kumar V, Cheng SC, Johnson MD, et al. Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nat Commun 2014; 5:4675.
37. Van de Veerdonk FL, Netea MG, Joosten LA, et al. Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy. FEMS Microbiol Rev 2010; 34:1063-1075.
38. Vazquez JA, Gupta S, Villanueva A. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis 1998; 17:781-783.
39. Vazquez JA, Hidalgo JA, De Bono S. Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. HIV Clin Trials 2000; 1:23-29.
40. Kullberg BJ, Vandewoude K, Herbrecht R, et al. A double-blind, randomized, placebo-controlled phase II study of filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients [abstract J-100]. In: 38th Interscience Current opinion-Fungal immunotherapy 26 Conference on Antimicrobial Agents and Chemotherapy; San Diego: American Society for Microbiology; 1998. p. 479.
41. Kullberg BJ, van 't Wout JW, Hoogstraten C, van Furth R. Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168:436-443.
42. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185-2191.
43. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26:1105-1113.
44. Leentjens J, Kox M, van der Hoeven JG, et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med 2013; 187:1287-1293.
45. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13:260-268.
46. Lukaszewicz AC, Grienay M, Resche-Rigon M, et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009; 37:2746-2752.
47. Leentjens J, Kox M, Koch RM, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med 2012; 186:838-845.
48. Unsinger J, Burnham CA, McDonough J, et al. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 2012; 206:606-616.
49. Delsing CE, Gresnigt MS, Leentjens J, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis 2014; 14:166.
50. Ibrahim AS, Luo G, Gebremariam T, et al. NDV-3 protects mice from vulvovaginal candidiasis through T-and B-cell immune response. Vaccine 2013; 31:5549-5556.
51. Schmidt CS, White CJ, Ibrahim AS, et al. NDV-3, a recombinant alumadjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 2012; 30:7594-7600.
52. Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG 2014. [Epub ahead of print]